Cite
Niu J, Andres G, Kramer K, et al. Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015;8:3323-8doi: 10.2147/OTT.S92443.
Niu, J., Andres, G., Kramer, K., Kundranda, M. N., Alvarez, R. H., Klimant, E., Parikh, A. R., Tan, B., Staren, E. D., & Markman, M. (2015). Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. OncoTargets and therapy, 83323-8. https://doi.org/10.2147/OTT.S92443
Niu, Jiaxin, et al. "Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients." OncoTargets and therapy vol. 8 (2015): 3323-8. doi: https://doi.org/10.2147/OTT.S92443
Niu J, Andres G, Kramer K, Kundranda MN, Alvarez RH, Klimant E, Parikh AR, Tan B, Staren ED, Markman M. Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015 Nov 11;8:3323-8. doi: 10.2147/OTT.S92443. eCollection 2015. PMID: 26648736; PMCID: PMC4648593.
Copy
Download .nbib